Efficacy and Safety of Acetaminophen and Aspirin Versus Placebo in the Acute Treatment of Migraine

• Status: Completed
• Trial end date: 2014-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study is to evaluate the efficacy and safety of acetaminophen and aspirin versus placebo in the acute treatment of migraine

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novartis
• Treatments: Acetaminophen; Aspirin

Criteria

Inclusion criteria:

1. Male or female aged 18 years and over.

2. International Headache Society (IHS) diagnosis of migraine without aura or typical aura with migraine headache.

3. History of experiencing at least 1, but not more than 8, acute migraine attacks monthly during the previous year.

4. History of at least moderate migraine pain intensity, if left untreated.

5. History of frequently or always experiencing nausea with the migraine attack.

Exclusion criteria:

Subjects eligible for inclusion in this study must not fulfill any of the following criteria:

1. Headache symptoms which may be due to or aggravated by:

• Recent (within 6 months) head or neck trauma (e.g., whiplash)

• Head or neck pain secondary to an orthopedic abnormality

• Cluster headache

• Specific migraine variants (e.g., basilar-type artery migraine, opthalmoplegic migraine, hemiplegic migraine, migraine aura without headache)

• Other serious, non-migraine causes of headache (e.g., increased intracranial pressure, intracranial bleeding, meningitis, malignancy)

• Non-serious, non-migraine causes of headache (e.g., cold, flu, hangover)

2. History of vomiting during more than 20% of migraine attacks.

Other protocol-defined inclusion/exclusion criteria may apply